Patient Reading Guide • Plain Field Notes
Typing ipamorelin injections into a search box often brings up sales pages and hard lab terms. This site is an open reading guide, not a clinic, drug shop, or seller. As of October 2026, ipamorelin is not approved by the US Food and Drug Administration for any human use.
Quick Note
Team members at Novo Nordisk first made ipamorelin in 1998 as a short chain of five parts. It acts like ghrelin, a gut hunger signal, to nudge the brain gland to release growth hormone.
In its October 2024 review, the FDA said plain ipamorelin and ipamorelin acetate are two distinct raw drugs. Both forms hold lab-made parts not found in nature, so checking a vial is hard.
Calling a drug a peptide just means it is a small chain of parts, not that it is legal. Common drugs like insulin are peptides, and so are many untested lab drugs.
In 1998 pig tests, ipamorelin raised growth hormone without raising stress signals even at 200 times the base dose. That early pig result made it famous online, though animal tests do not prove human safety.
Common Myth
People often hear that ipamorelin shots are an approved care option since the name shows up in public drug lists.
As of October 2026, ipamorelin is not an FDA-approved drug and is not in any approved medicine. Checks of Drugs@FDA and DailyMed in October 2026 show 0 approved files and 0 drug labels for ipamorelin.
Makers have listed raw ipamorelin powder in the National Drug Code list, where 2026 files show bulk powder entries only. Federal law says a code never means FDA approval, and claiming it does breaks legal rules.
One drug in the same class, macimorelin, is an oral drink test for adult growth hormone lack, not approved as care. In its October 2024 review, the FDA said no drug in this class is approved to treat adults.
Sermorelin is a separate peptide whose old brand Geref left the US market in June 2009 and stays off the market in 2026.
Common Myth
Some clinics claim the FDA cleared ipamorelin for custom mixing when past requests were pulled back.
On the FDA bulk drug page current as of April 22, 2026, ipamorelin acetate stays in Category 2 for 503B sites over safety concerns. On October 29, 2024, the FDA panel voted 0 yes, 12 no, and 1 abstain on each form.
Under section 503A rules, a local pharmacy may mix a bulk powder only if it passes one of three legal tests. It must have an official quality standard, be in an FDA-approved drug, or sit on the 6-item bulk list in 2026.
In its 2024 review, the FDA found that plain ipamorelin and ipamorelin acetate fail all three mixing tests. Pulling back a request never clears a drug, and on the April 22, 2026 page ipamorelin acetate keeps its September 29, 2023 503B listing. As of October 1, 2026, the FDA has issued no final rule putting ipamorelin on the 503A or 503B lists.
Ask if your health goal has a proven drug with a full human track record.
If someone suggests a custom peptide shot, ask which shop mixes it and how it meets federal rules.
Lane Guide
People use one word for three very different paths. Use the buttons below to see how each lane works.
The approved lane, as of September 2026, includes Wegovy and Ozempic (semaglutide) plus Zepbound and Mounjaro (tirzepatide), all FDA-approved drugs checked before sale.
Ipamorelin is not in this lane since it stays not approved for human use in October 2026.
State 503A shops and 503B sites mix custom orders, which are not approved or checked for safety by the FDA before sale.
As of October 2026, ipamorelin fails the 503A bulk tests and ipamorelin acetate sits in 503B Category 2.
In August 2026 warning letters, the FDA called lab-labeled tesamorelin and ipamorelin blends unapproved new drugs sold in an illegal way.
Selling mixing water and dose tools beside a vial showed the FDA in August 2026 that sellers meant it for human shots.
Every fact on this page comes from these public health and science records.